Hematology Frontier

On August 24, 2024, the 12th Lu Daopei Hematology Forum successfully concluded. At the forum, Dr. Zhenyu Li from The Affiliated Hospital of Xuzhou Medical University delivered a compelling presentation titled "GPRC5D CAR-T Therapy for Relapsed and Refractory Multiple Myeloma". He shared insights into the application of GPRC5D-targeted CAR-T cells and BCMA/GPRC5D dual-target CAR-T cells in relapsed and refractory multiple myeloma (R/R MM), as well as the commonalities and differences observed in clinical studies of various types of CAR-T cells. Hematology Frontier presents a summary of the key points from his presentation for our readers.

A recent study published in Blood (November 2024) has identified Hepatic-like Erythropoietin Polycythemia (HEP) as a novel cause of hereditary and acquired erythrocytosis. Researchers discovered mutations in the EPO gene,…

A recent study published in Blood (November 2024) presents results from the Phase 3 inMIND trial, evaluating the addition of tafasitamab to lenalidomide and rituximab in patients with relapsed or…

The advent of tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of chronic myeloid leukemia (CML), transforming its management into a chronic disease model and bringing patient life expectancy close to that of the general population. However, some patients experience treatment failure due to intolerance or insufficient response to at least two existing therapies, or the development of resistance, with consecutive changes in TKIs being associated with an increased risk of treatment failure. Patients with prior treatment intolerance, not achieving major molecular response (MMR) within two years, or with BCR-ABL gene mutations may develop resistance to current TKIs, increasing the risk of disease progression. Moreover, as treatment duration extends, patient demands for treatment tolerability increase. Balancing disease treatment with quality of life is particularly important for long-term survival. During the recent 12th Annual Meeting of the Society for Hematologic Oncology (SOHO 2024), "Hematology Frontier" had the honor of interviewing Dr. Jorge E. Cortes, Director of the Georgia Cancer Center at the Medical College of Georgia, who discussed the profound impact of Asciminib on current CML treatment patterns and future therapeutic landscapes, based on key findings from the ASC4FIRST study.

Diffuse large B-cell lymphoma (DLBCL), as the most common subtype of non-Hodgkin lymphoma, is highly heterogeneous and poses challenges in treatment. Patient prognosis is influenced by various factors, and while the standard R-CHOP regimen is widely used, its efficacy is limited for high-risk groups such as patients with double-hit lymphoma (DHL), necessitating more precise treatment plans. The 12th Annual Meeting of the Society for Hematologic Oncology (SOHO 2024) took place from September 4th to 7th, 2024, in Houston, USA, attracting top experts in the field of hematologic malignancies from around the world to exchange the latest research findings and discuss new strategies for treatment. During the conference, "Hematology Frontier" specially invited Dr. Grzegorz S. Nowakowski from the Mayo Clinic Comprehensive Cancer Center to analyze the latest advances in the treatment of DLBCL and the future direction of treatment strategies, aiming to provide important guidance for clinicians in optimizing treatment plans and making precise therapeutic choices.

Lymphoma is a common malignant disease of the lymphatic system that poses a significant threat to public health. China faces a rapidly increasing burden of lymphatic tumors. The GBD 2019 study shows that China accounts for 10.8% of the world's new cases of Hodgkin lymphoma and 9.8% of the deaths, as well as 20.1% of the new cases and 17.4% of the deaths from non-Hodgkin lymphoma. Therefore, improving lymphoma diagnosis and treatment levels is a critical challenge in China. To gain a deeper understanding of the current status and progress of lymphoma diagnosis and treatment in China, Hematology Frontier interviewed Dr. Luguo Qiu, Director of the Lymphoma Diagnosis and Treatment Center at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences , for an in-depth analysis of this topic.

September 4 marks "World Leukemia Day," an initiative launched by the Acute Leukemia Advocates Network, CLL Advocates Network, CML Advocates Network, and Leukaemia Care. The day is dedicated to raising global awareness about leukemia, promoting efforts in prevention, diagnosis, treatment, and recovery. Leukemia, often called "blood cancer," is a complex disease with high treatment costs and the risk of relapse, placing a heavy burden on many families. However, through awareness and action on this day, we aim to break the silence and helplessness, and collectively ignite a beacon of hope for leukemia patients.

To foster interdisciplinary integration in hematology, accelerate the innovation and translation of scientific research, promote high-quality development of the discipline, and contribute to the Healthy China Initiative, the 5th Annual Meeting of Chinese Alliance for Societies of Hematology (CASH) will be held from January 3rd to 5th, 2025, in Tianjin.

From December 7 to 10, 2024, the 66th American Society of Hematology (ASH) Annual Meeting took place in San Diego, USA, bringing together global experts to discuss the latest advancements in hematology. During this prestigious event, Dr. Minghui Duan from Peking Union Medical College Hospital presented his team’s latest findings on myelofibrosis (MF) treatment (Abstract #1002), offering new perspectives for future therapeutic strategies. To provide deeper insights, Hematology Frontier invited Professor Duan for an in-depth discussion on his research.